Cancer Annihilator? New Drug Obliterates Tumors in 80% of Sarcoma Patients

A groundbreaking new drug, tigilanol tiglate, achieved an 80% objective response rate in patients with a rare and aggressive cancer, soft tissue sarcoma (STS)^{1, 4}.
In the Phase IIa trial, 52% of treated tumors were completely eradicated, and none of these tumors recurred within the six-month follow-up period, suggesting a durable effect⁷.
The therapy was well-tolerated with manageable side effects, paving the way for the next stage of clinical trials at Memorial Sloan Kettering Cancer Center³.

In a stunning development for oncology, a novel drug is showing unprecedented power against a notoriously difficult-to-treat cancer. For patients battling advanced soft tissue sarcoma (STS)—a rare cancer with limited effective treatments—a beacon of hope has emerged from a Phase IIa clinical trial (NCT05755113). The drug, tigilanol tiglate, developed by Australian life sciences company QBiotics, was injected directly into tumors, unleashing a potent, localized attack.

The results from the trial's first stage are nothing short of remarkable. An astonishing 80% of patients saw their injected tumors shrink or disappear completely. Diving deeper, the data reveals that of the 27 tumors treated, 52% were completely annihilated—a 100% reduction in volume. Even more critically, in the six months following treatment, none of these eradicated tumors returned, pointing to a potentially lasting cure at the treatment site^{1, 7}.

Tigilanol tiglate, which has a successful veterinary formulation (STELFONTA®) for treating tumors in dogs, was found to be well-tolerated in human patients, with most side effects like pain and swelling occurring locally at the injection site.

These promising results have propelled the study into its second stage, expanding the investigation into this potential game-changer. For the 128,000 people diagnosed with STS globally each year, this trial represents a monumental step forward in a field desperate for new weapons^{2, 5}.

Cancer Annihilator? New Drug Obliterates Tumors in 80% of Sarcoma Patients

References

Stay Updated!